Evogene (NASDAQ:EVGN – Get Free Report) and Coya Therapeutics (NASDAQ:COYA – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Volatility and Risk
Evogene has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Earnings and Valuation
This table compares Evogene and Coya Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evogene | $1.66 million | 1.90 | -$8.48 million | ($0.91) | -0.40 |
| Coya Therapeutics | $4.69 million | 16.36 | -$21.23 million | ($1.39) | -2.35 |
Evogene has higher earnings, but lower revenue than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
10.4% of Evogene shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Evogene and Coya Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evogene | -694.18% | -156.53% | -86.80% |
| Coya Therapeutics | -643.44% | -66.91% | -60.13% |
Analyst Ratings
This is a summary of recent ratings and price targets for Evogene and Coya Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
| Coya Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
Coya Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 358.72%. Given Coya Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than Evogene.
Summary
Coya Therapeutics beats Evogene on 9 of the 14 factors compared between the two stocks.
About Evogene
Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms. Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis.
About Coya Therapeutics
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
